Comparative efficacy, safety, and effect on quality of life of triamcinolone acetonide and fluticasone propionate aqueous nasal sprays in patients with fall seasonal allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 89, Issue 1, 2002, Pages 56-62

  Gross, Gary ^a   Jacobs, Robert L ^b   Woodworth, Thomas H ^c   Georges, George C ^c   Lim, Janet C ^c  

^a Dallas Allergy & Asthma Center   (United States)

^b Biogenics Research Institute   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE; NASACORT AQ; TRIAMCINOLONE ACETONIDE;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RHINITIS; SINGLE BLIND PROCEDURE; SNEEZING; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036666834     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61911-4     Document Type: Article

References (16)

1. American Academy of Allergy, Asthma, and Immunology. The Allergy Report. 2000;3:51-58. www.theallergyreport.org.
2. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 1998;101:S434-S439.
3. National Asthma Education and Prevention Program. Expert Panel Report II. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health Publication, May 1997.
4. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 1998;48:956-960.
5. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994;59:597-602.
6. Umland SP, Nahrebne DK, Razac S, et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-γ production by cultured primary CD4+ T cells. J Allergy Clin Immunol 1997;100:511-519.
7. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids. Drug Saf 2000;23:11-33.
8. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 health status questionnaire. J Allergy Clin Immunol 1994;94:182-188.
9. Tanner LA, Reilly M, Meltzer EO, et al. Effect of fexofenadine HCl on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manag Care 1999;5(Suppl):S235-S247.
10. Blaiss MS. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 1999;83:449-454.
11. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99:S742-S749.
12. Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann Allergy Asthma Immunol 1997;79:370-378.
13. Small P, Houle P, Day JH, et al. A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. J Allergy Clin Immunol 1997;100:592-595.
14. Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. In press.
15. Gerson I, Green L, Fishken D. Patient preference and sensory comparisons of nasal spray allergy medications. J Sensory Stud 1999;14:491-496.
16. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994;93:413-421.